Compare · PRME vs RVMD
PRME vs RVMD
Side-by-side comparison of Prime Medicine Inc. (PRME) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRME and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $43.59B, about 71.7x PRME ($607.6M).
- RVMD has been more active in the news (14 items in the past 4 weeks vs 3 for PRME).
- RVMD has more recent analyst coverage (25 ratings vs 18 for PRME).
- Company
- Prime Medicine Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- $607.6M
- $43.59B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2020
- News (4w)
- 3
- 14
- Recent ratings
- 18
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest PRME
- Prime Medicine to Participate in Upcoming Investor Conferences
- Chardan Capital Markets resumed coverage on Prime Medicine with a new price target
- BMO Capital Markets initiated coverage on Prime Medicine with a new price target
- SEC Form 10-Q filed by Prime Medicine Inc.
- Prime Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
- Prime Medicine Inc. filed SEC Form 8-K: Other Events
- Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
- Prime Medicine upgraded by H.C. Wainwright with a new price target
Latest RVMD
- Director Kim Lorence H. sold $3,585,837 worth of shares (17,090 units at $209.82) as part of a pre-agreed trading plan (SEC Form 4)
- Morgan Stanley initiated coverage on Revolution Medicines with a new price target
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
- Director Kim Lorence H. sold $11,381,288 worth of shares (56,000 units at $203.24) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- FDA Approval for RASONQUE issued to REVOLUTION MEDICINES INC
- Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution
- Revolution Medicines Inc. filed SEC Form 8-K: Other Events
- U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- General Counsel Cislini Jeff exercised 56,280 shares at a strike of $20.00 and sold $11,904,247 worth of shares (56,894 units at $209.24) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 55,907 units (SEC Form 4)